Recently, the United States listed Helicobacter pylori chronic infection as a clear carcinogen and detonated A-share “anti Helicobacter pylori” concept stock.
On January 7, the popularity of the concept of “anti Helicobacter pylori” continued. Among them, Zhejiang Yatai Pharmaceutical Co.Ltd(002370) , Shanghai Jiaoda Onlly Co.Ltd(600530) rose again, realizing two connected boards and three connected boards respectively. Beijing Strong Biotechnologies Inc(300406) , Guangzhou Wondfo Biotech Co.Ltd(300482) and Yabao Pharmaceutical Group Co.Ltd(600351) rose more than 6%. The previous Juneyao Grand Healthy Drinks Co.Ltd(605388) and Beijing Scitop Bio-Tech Co.Ltd(300858) that rose sharply showed signs of “flameout”.
listed companies responded to
On December 21, 2021, the U.S. Department of health and human services issued the 15th edition of carcinogen report. Compared with the 14th edition, 8 substances were added this time, “Helicobacter pylori chronic infection” was listed as a human carcinogen in the report for the first time.
According to experts, the infection rate of Helicobacter pylori in natural populations around the world exceeds 50%. In China, the probability of Helicobacter pylori infection varies significantly in different regions, with an average infection rate of 59%, of which the average infection rate of children is 40%.
Following the sharp rise on January 5, on January 6, Juneyao Grand Healthy Drinks Co.Ltd(605388) , Beijing Scitop Bio-Tech Co.Ltd(300858) , Zhejiang Yatai Pharmaceutical Co.Ltd(002370) , Shanghai Jiaoda Onlly Co.Ltd(600530) , Guobang Pharma Ltd(605507) and other “anti Helicobacter pylori concept stocks” rose one after another.
On January 6, Juneyao Grand Healthy Drinks Co.Ltd(605388) , Beijing Scitop Bio-Tech Co.Ltd(300858) , Shanghai Jiaoda Onlly Co.Ltd(600530) successively issued stock price change announcements to explain the hot spots concerned by the market.
“The first probiotic stock” Beijing Scitop Bio-Tech Co.Ltd(300858) rose more than 30% in two trading days. The company announced that the company is a high-tech enterprise mainly engaged in the R & D, production and sales of compound food additives, edible probiotic products and animal and plant probiotics. In recent years, the company has conducted scientific experiments and clinical verification on the anti Helicobacter pylori efficacy of some core strains, and is applying for relevant patents. There are uncertainties in the final results of relevant scientific experiments, clinical validation and whether the patent application can be authorized.
The share price of Juneyao Grand Healthy Drinks Co.Ltd(605388) rose by more than 21% for three consecutive trading days. The company announced that at present, the company’s main business is still lactic acid bacteria drinks, and the company’s chewing tablets, drinks and other products related to Helicobacter pylori are still in the investment stage. As of the first three quarters of 2021, the revenue of the above products accounted for less than 5% of the company’s operating revenue (this data is Unaudited), which has little impact on the company’s operating performance.
Shanghai Jiaoda Onlly Co.Ltd(600530) rose more than 20% for three consecutive trading days. The company said that the company’s Probiotic product “ANGLI super Keyou probiotic powder” mentioned in the market related to the concept of anti Helicobacter pylori is no longer produced.
On January 7, Shanghai Jiaoda Onlly Co.Ltd(600530) raised the limit again to realize the triple board.
The market heat is not decreasing, and investors have run to the interactive platform to ask questions. In addition to the drugs for the treatment of Helicobacter pylori, some listed companies were also asked whether they have Helicobacter pylori testing products.
On January 7, several companies responded on the interactive platform.
Hybio Pharmaceutical Co.Ltd(300199) : the company’s product pipeline has clarithromycin sustained release tablets for the treatment of Helicobacter pylori.
Chongqing Pharscin Pharmaceutical Co.Ltd(002907) : Omeprazole Sodium Bicarbonate capsule, the company’s product, has the effect of inhibiting gastric acid. It can be used in combination with bismuth and antibiotics for the “triple” or “quadruple” treatment of Helicobacter pylori.
Jiangsu Yuyue Medical Equipment And Supply Co.Ltd(002223) : the company’s gastric Helicobacter pylori antibody test kit has been put on the e-commerce platform, and clear and reliable test results can be obtained as soon as 15 minutes.
Beijing Bohui Innovation Biotechnology Group Co.Ltd(300318) : the company is developing a multiple respiratory virus detection kit, but it does not include Helicobacter pylori detection.
“anti secluded” toothpaste rub hot spots! The authority responded
Recently, due to the attention paid to Helicobacter pylori, toothpaste and other products related to anti Helicobacter pylori on major e-commerce platforms have been selling hot. Some products are labeled with “national patent” and “special treatment of Helicobacter pylori”, and even rub the hot spots of listed companies, and are sold on major platforms under the “name” of listed companies. In terms of price, the price of a single toothpaste varies from tens of yuan to 100 yuan, which is 3-10 times the price of conventional toothpaste of the same specification
source: Taobao
The above behavior has attracted the attention of regulators.
The State Food and Drug Administration announced on January 7 that at present, there are some hot-selling products named “toothpaste” on the market, claiming to have the effects of “anti Helicobacter pylori” and “removing halitosis through anti Helicobacter pylori”. Many of these products are not toothpaste in the real sense.
The State Food and Drug Administration said that toothpaste can not express or imply medical effects, and can not make false or misleading efficacy claims. At present, the State Food and drug administration is speeding up the formulation of departmental regulations for toothpaste management, toothpaste supervision and administration measures, and will promote the promulgation of the regulations as soon as possible.
The State Food and drug administration also said that Helicobacter pylori mainly exists in the human stomach. There is no evidence that brushing teeth with toothpaste can affect Helicobacter pylori in the stomach. In addition, the oral cavity is a complex environment in which a variety of bacteria and other microorganisms coexist. Studies have shown that Helicobacter pylori that may exist in the mouth is mainly concentrated in saliva and plaque. The correlation between oral Helicobacter pylori and digestive system diseases such as periodontal disease, halitosis and gastric cancer is still lack of evidence-based medical evidence. Toothpaste and other products that claim to have “anti Helicobacter pylori” may have added broad-spectrum bacteriostatic agents. If a large number of broad-spectrum bacteriostatic agents are used for a long time, it may lead to the disorder of oral flora, which is not conducive to oral health.
(source: China Securities Journal)
